methyl 3-[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2R,4R,5S,6S)-5-acetyloxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-4-(dimethylamino)-6-methyloxan-3-yl]oxypropanoate | 1104201-61-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 3-[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2R,4R,5S,6S)-5-acetyloxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-4-(dimethylamino)-6-methyloxan-3-yl]oxypropanoate
• CAS: 1104201-61-7
• 化学式: C₄₄H₈₀N₂O₁₅
• 分子量: 877.124
• InChiKey: SIPKGZWYJDUDMI-KFEUMMRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  61
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  201
• 氢给体数：
  3
• 氢受体数：
  17

反应信息

• 作为反应物：
  描述：

  methyl 3-[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2R,4R,5S,6S)-5-acetyloxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-4-(dimethylamino)-6-methyloxan-3-yl]oxypropanoate 在 lithium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 生成 2'-O-(2-carboxyethyl)-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A
  参考文献：
  名称：

  Compounds

  摘要：

  本发明涉及具有抗疟活性的新型2'-O-取代的9-去氧-9a-甲基-9a-氮-9a-同异红霉素A衍生物。更具体地，本发明涉及具有抗疟活性的2'-O-取代-9-去氧-9a-甲基-9a-氮-9a-同异红霉素A和2'-O-取代-3-O-去氧-9-去氧-9a-甲基-9a-氮-9a-同异红霉素A衍生物，以及它们的制备中间体、制备方法、用作治疗剂的用途以及具有抗疟活性的盐。

  公开号：

  US20090036388A1
• 作为产物：
  描述：

  阿奇霉素 在 甲醇 、 4-二甲氨基吡啶 、 甲酸 、 sodium hydride 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 52.0h， 生成 methyl 3-[(2S,3R,4S,6R)-2-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2R,4R,5S,6S)-5-acetyloxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-4-(dimethylamino)-6-methyloxan-3-yl]oxypropanoate
  参考文献：
  名称：

  Design, Synthesis, and in Vitro Activity of Novel 2′-O-Substituted 15-Membered Azalides

  摘要：

  Malaria remains one of the most widespread human infectious diseases, and its eradication will largely depend on antimalarial drug discovery. Here, we present a novel approach to the development of the azalide class of antimalarials by describing the design, synthesis, and characterization of novel 2'-O-substituted-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A derivatives consisting of different quinoline moieties covalently liked to a 15-membered azalide scaffold at position 2'. By multistep straightforward synthesis, 19 new, stable, and soluble compounds were created and biologically profiled. Most active compounds from the 4-amino-7-chloroquinoline series showed high selectivity for P. falciparum parasites, and in vitro antimalarial activity improved 1000-fold over azithromycin. Antimalarial potency was equivalent to chloroquine against the sensitive strain (3D7A) and up to 48-fold enhanced over chloroquine against the chloroquine-resistant strain (W2). Concurrently, the antibacterial activity of the compounds was eliminated, thus facilitating the development of malaria-specific macrolide agents.

  DOI：

  10.1021/jm201676t